Hormone replacement therapy and cardiovascular risk
- 1 July 2000
- journal article
- clinical trial
- Published by Springer Nature in Current Cardiology Reports
- Vol. 2 (4) , 288-292
Abstract
We are reexamining the role of hormone replacement therapy in cardiovascular risk in light of the results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. Prior to this trial, the wealth of evidence in the laboratory and in observational trials suggested that estrogen replacement was associated with significant cardioprotection. The HERS trial was the first randomized trial of this therapy in postmenopausal women with coronary artery disease, and it did not demonstrate a reduction in cardiovascular events in women taking hormone replacement therapy. These findings have made us rethink some of the basic science underlying the cardiovascular effects of hormone replacement therapy. Recent evidence regarding thromboembolic risk, inflammation, and types of hormone replacement therapy is discussed.Keywords
This publication has 27 references indexed in Scilit:
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in WomenNew England Journal of Medicine, 2000
- The Protective Effects of Estrogen on the Cardiovascular SystemNew England Journal of Medicine, 1999
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Endogenous Estrogen and Acetylcholine-Induced Vasodilation in Normotensive WomenHypertension, 1997
- Gonadal hormone substitutes: Effects on the cardiovascular systemOsteoporosis International, 1997
- Prospective study of exogenous hormones and risk of pulmonary embolism in womenThe Lancet, 1996
- Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogensThe Lancet, 1996
- Risk of venous thromboembolism in users of hormone replacement therapyThe Lancet, 1996
- Estrogen and the blood vessel wallCurrent Opinion in Cardiology, 1994
- Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1.Journal of Clinical Investigation, 1994